SCHEMBL20704836

SCHEMBL20704836

COc1cc(NC(=O)c2c[nH]c3cc(OC)c(OC)c(OC)c3c2=O)cc(OC)c1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 1/20 0.47
▸ MTNR1B P49286 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ HTT P42858 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ TP53 P04637 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ PKM P14618 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ ATM Q13315 1/20 0.43
▸ TOP1 P11387 1/20 0.43
▸ TUBB1 Q9H4B7 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ESR1 P03372 1/20 0.42
▸ GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20704840 0.90 CFTR (0.54) MTNR1AMTNR1BALDH1A1HTTLMNA
SCHEMBL30309869 0.90 CFTR (0.54) MTNR1AMTNR1BALDH1A1HTTLMNA
SCHEMBL20704809 0.89 POLB (0.51) MTNR1AMTNR1BALDH1A1LMNASMN1; SMN2
SCHEMBL20704864 0.88 TUBB1 (0.46) ALDH1A1HTTLMNASMN1; SMN2TP53
SCHEMBL30309868 0.86 SMN1; SMN2 (0.48) MTNR1AMTNR1BALDH1A1LMNASMN1; SMN2
SCHEMBL20704653 0.86 SMN1; SMN2 (0.48) MTNR1AMTNR1BALDH1A1LMNASMN1; SMN2
SCHEMBL20704823 0.84 CFTR (0.46) MTNR1AMTNR1BSMN1; SMN2TP53HPGD
SCHEMBL20704802 0.82 MEN1 (0.50) MTNR1AMTNR1BALDH1A1HTTLMNA
SCHEMBL30309867 0.82 MEN1 (0.50) MTNR1AMTNR1BALDH1A1HTTLMNA
SCHEMBL20704872 0.82 MTNR1A (0.50) MTNR1AMTNR1BALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113225-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-13 — — US disclosed
US-20230103887-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL THERAPEUTICS, INC. (US) 2023-04-06 — — US disclosed
US-11505528-B2 Inhibitors of microbially induced amyloid AXIAL THERAPEUTICS, INC. (US) 2022-11-22 — — US disclosed
US-11505528-B2 Inhibitors of microbially induced amyloid AXIAL THERAPEUTICS, INC. (US) 2022-11-22 — — US disclosed
WO-2022098879-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-12 — — WO disclosed
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2022-05-05 — — US disclosed
US-20210052503-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL THERAPEUTICS, INC. (US) 2021-02-25 — — US disclosed
WO-2020227437-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME AXIAL BIOTHERAPEUTICS, INC. (US) 2020-11-12 — — WO disclosed
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2020-09-17 — — US disclosed
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2020-09-17 — — US disclosed
EP-3664822-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID Axial Biotherapeutics, Inc. (US) 2020-06-17 — — EP disclosed
WO-2019028456-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2019-02-07 — — WO disclosed
WO-2019028456-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID AXIAL BIOTHERAPEUTICS, INC. (US) 2019-02-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103887-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP MTNR1A 871/4885MTNR1B 1143/4885ALDH1A1 4090/4885
US-11505528-B2 Inhibitors of microbially induced amyloid SNCA, PARK7, PRNP MTNR1A 871/4885MTNR1B 1143/4885ALDH1A1 4090/4885
US-20230113225-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP MTNR1A 858/4885MTNR1B 995/4885ALDH1A1 4129/4885
US-20210052503-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME APC, SNCA, PARK7 MTNR1A 193/4885MTNR1B 791/4885ALDH1A1 1812/4885
US-20220133634-A1 SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME APC, SNCA, PARK7 MTNR1A 193/4885MTNR1B 791/4885ALDH1A1 1812/4885
US-20200290970-A1 INHIBITORS OF MICROBIALLY INDUCED AMYLOID SNCA, PARK7, PRNP MTNR1A 871/4885MTNR1B 1143/4885ALDH1A1 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback